Reza Nekouian | Genetics and Molecular Biology | Pioneer Researcher Award

Published on by Citation Awards

Reza Nekouian | Genetics and Molecular Biology | Pioneer Researcher Award

Dr Reza Nekouian, Iran University of Medical Sciences, IUMS, Iran

Dr. Reza Nekouian, a seasoned faculty member at Iran University of Medical Sciences, brings over 17 years of expertise in cancer genetics and molecular diagnostics. Born on March 21, 1978, in Tehran, Iran, he has built a strong reputation in research design, academic teaching, and innovative cancer research solutions. Known for his problem-solving and leadership skills, Dr. Nekouian excels in guiding research teams and translating molecular findings into clinical applications. His academic contributions span across cancer genetics, molecular biology, and personalized medicine. In addition to being a dedicated educator in medical genetics and genetic engineering, he is also widely published in reputable journals. Dr. Nekouian is recognized for his collaborative spirit, exceptional communication, and passion for scientific innovation. His work significantly impacts early cancer detection and personalized treatments, aligning science with real-world health solutions.

Publication Profile

google scholar

Education

Dr. Reza Nekouian received his Ph.D. in Medical Biotechnology from Pune University, India, in 2007, where he specialized in cancer molecular biology and therapeutics. Prior to that, he completed his Master of Science (M.Sc.) in Health Sciences (Genetics) at the University of Pune in 2003. His academic journey reflects a focused pursuit of excellence in biotechnology and genetics, laying the foundation for his later contributions in cancer research and medical education. His studies in India exposed him to a rich scientific environment and equipped him with the latest tools in molecular genetics and biomedical research. These formative years nurtured his deep interest in translational medicine, setting him on a path to combine lab-based innovations with clinical cancer diagnostics. Dr. Nekouian’s educational background continues to fuel his research on biomarkers, cancer therapeutics, and molecular diagnostics, making him a valuable contributor to the global scientific and medical community.

Experience

Dr. Reza Nekouian has served as a faculty member and researcher at Iran University of Medical Sciences (IUMS) since February 2012. His core responsibilities include designing and managing cutting-edge research projects in cancer genetics, molecular diagnostics, and biomarker development for early cancer detection. He also actively contributes to advancing personalized medicine approaches in oncology. As a dedicated educator, Dr. Nekouian teaches theoretical and practical courses in medical genetics and genetic engineering, inspiring the next generation of scientists and clinicians. His professional journey spans over 17 years of impactful work at medical universities and research centers. He is recognized for his skill in resolving complex genetic and molecular research challenges, leading multidisciplinary teams, and publishing groundbreaking findings. With a focus on translational research, he bridges laboratory innovations with patient-centric medical applications, thereby improving diagnostic precision and therapeutic strategies in cancer treatment.

Awards and Honors

Although specific awards are not listed in the profile, Dr. Reza Nekouian’s extensive contributions to cancer genetics, personalized medicine, and molecular diagnostics have earned him academic distinction and professional recognition across Iranian and international research communities. His consistent publication in reputed journals, leadership in high-impact research, and role in educational development underscore his influence in the field. Dr. Nekouian has been instrumental in pioneering research programs and contributing to national strategies for cancer prevention and diagnosis. His invited roles in collaborative projects, advisory panels, and journal editorial activities serve as implicit recognition of his expertise. He is regularly consulted for complex research problem-solving and project development, particularly in molecular biology and biotechnology. Additionally, his leadership in implementing cancer control initiatives in the private health sector highlights his commitment to both scientific excellence and societal health advancement.

Research Focus

Dr. Reza Nekouian’s research centers on cancer genetics, with a specialized focus on the molecular mechanisms of tumorigenesis and biomarker discovery for early detection. His work explores the genetic regulation of cancer progression, using advanced diagnostic tools like circulating microRNAs and liposomal drug delivery systems. He also investigates personalized medicine approaches, including the role of gene expression and polymorphisms in cancer susceptibility and therapeutic response. A recurring theme in his research is the integration of molecular diagnostics with clinical oncology, aiming to improve diagnostic accuracy and treatment precision. Dr. Nekouian has contributed significantly to breast, gastric, and colorectal cancer research, evaluating biomarkers like miRNAs, HLA-G, and FOXP3, and exploring innovative cancer therapies using viral vectors and nanotechnology. His interdisciplinary approach blends molecular biology, bioinformatics, and pharmacogenomics to enhance patient outcomes and reduce cancer mortality through early, personalized interventions.

Publication Top Notes

📄 Evaluation of the in vitro and in vivo effect of liposomal doxorubicin with Newcastle disease virus on 4T1 cell line (2023)
📄 Plasma miR-183-5p as a predictive lymph node metastasis marker in colorectal cancer (2022)
📄 Effect of testosterone enanthate on liver Irs-2 mRNA expression in PCOS model rats (2021)
📄 Meta-analysis of serum HLA-G level accuracy in breast cancer diagnosis (2020)
📄 Expression of angiogenesis-related genes in Iranian breast cancer patients (2020)
📄 Epidemiological study of postsurgical invasive breast cancer cases in Iran (2020)
📄 Use of software in detecting angiogenesis in breast tissue slides (2020)
📄 Meta-analysis of FOXP3 polymorphisms and multiple sclerosis susceptibility (2020)
📄 Evaluation of miR-21 and miR-222 as diagnostic biomarkers for gastric cancer (2019)
📄 Nanocomposite scaffold with MSCs for bone repair applications (2019)
📄 Study on protein-binding malondialdehyde in breast cancer tissues (2019)
📄 Management of biotechnology industry in the West and solutions for Iran (2018)
📄 In vitro effects of Lactobacillus reuteri on gastric cancer progression (2017)
📄 Implementation of private sector cancer prevention programs in Iran (2017)
📄 Study on BRCA1/2 mutations in women with breast cancer family history (2016)
📄 Anti-fibronectin gold nanoparticle biosensor for ECM detection (2014)
📄 Iranian consumers’ shift to functional foods for healthier lifestyle (2014)
📄 FOXP3 mRNA downregulation by Alkanna Frigida extract (2013)
📄 H-semigroup structure on F-offspring of a gene pool (2012)

Elof Eriksson | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Published on by Citation Awards

Elof Eriksson | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Prof. Dr Elof Eriksson, Harvard Medical school, United States

Dr. Elof Eriksson, MD, PhD, is an esteemed plastic surgeon and researcher, born in Sweden. He earned his MD in 1969 and a PhD in Physiology in 1972 from the University of Göteborg. After relocating to the United States in 1973, he trained in general surgery at the University of Chicago and plastic surgery at the Medical College of Virginia. He has held key academic and clinical roles, notably as Chief of Plastic Surgery at Brigham and Women’s Hospital and Children’s Hospital in Boston. In 1996, he was named the first Joseph E. Murray Professor of Plastic Surgery at Harvard Medical School. Renowned for his pioneering work in wound healing, Dr. Eriksson also established several specialized programs, including face transplantation. After stepping down as Chief in 2016, he became Professor Emeritus. Dr. Eriksson’s legacy includes over 200 publications, 50 patents, and numerous prestigious awards in surgery and biomedical research.

Publication Profile

scopus

Education

Dr. Eriksson began his medical and scientific journey in Sweden, where he earned an MD in 1969 and a PhD in Physiology in 1972 from the University of Göteborg. His dual degree underscores his deep commitment to both clinical excellence and biomedical research. Following his move to the United States in 1973, he pursued further training in surgery, completing his general surgery residency at the University of Chicago. He then specialized in plastic surgery, finishing his residency at the Medical College of Virginia. This strong educational foundation prepared Dr. Eriksson for a distinguished international career that bridged academic medicine, clinical innovation, and research leadership. His training in both physiology and surgery uniquely positioned him to develop translational research programs in wound healing and plastic surgery that have had a global impact. His dedication to academic medicine led to his appointment as the first Joseph E. Murray Professor of Plastic Surgery at Harvard Medical School.

Experience

Dr. Elof Eriksson has over four decades of clinical, academic, and research experience. After his U.S.-based surgical training, he returned to Sweden to serve as an attending plastic surgeon at the University of Göteborg for three years. In 1982, he became the Director of the Burn Center at Southern Illinois University, where he focused on acute care and wound management. In 1986, he was recruited to Brigham and Women’s Hospital and Children’s Hospital in Boston as Chief of Plastic Surgery, a role he held until 2016. Under his leadership, the division expanded from 1 to 19 faculty members, and he initiated groundbreaking programs in wound care, microsurgery, breast reconstruction, and face transplantation. In 1996, he was named the Joseph E. Murray Professor of Plastic Surgery at Harvard Medical School. He also served on various national boards and hospital committees, reflecting his leadership in clinical governance and academic surgery.

Awards and Honors

Dr. Eriksson’s groundbreaking contributions in plastic surgery and wound healing have earned him numerous awards and honors. He was the recipient of the Harvard Plastic Surgery Teaching Award, recognizing his excellence in academic mentorship. His lifetime achievements were celebrated with the Boswick Lifetime Achievement Award from the Symposium on Advanced Wound Care and the Lifetime Achievement Award from the Wound Healing Society. For his pioneering research, he was also honored by the American Association of Plastic Surgeons and the Plastic Surgery Foundation. Beyond accolades, he served in leadership roles including President of the Wound Healing Society and the Wound Healing Foundation, and a board member of the American Board of Plastic Surgery. His extensive service was also recognized through his appointment to the Board of Trustees at Dartmouth Hitchcock Medical Center. These honors reflect both his clinical excellence and his significant impact on translational and surgical sciences.

Research Focus

Dr. Elof Eriksson’s research focuses on wound healing, integrating basic science, translational research, and clinical innovation. He has explored advanced methodologies ranging from gene transfer techniques to strategies that regulate the wound microenvironment in response to acute trauma. His laboratory has led numerous federally funded studies, including substantial support from the National Institutes of Health (NIH) and the U.S. Department of Defense, aimed at improving wound care for trauma patients and military personnel. Dr. Eriksson’s research has significantly advanced our understanding of tissue regeneration, inflammation control, and post-injury cellular behavior. He has published over 200 peer-reviewed articles and is the first author of more than 50 patents, many of which have led to innovative therapies in clinical use. His work bridges the gap between lab research and surgical application, particularly in developing new treatments for complex wounds, burn injuries, and reconstructive surgery.

Publication Top Notes

  • “Gene transfer strategies for wound healing optimization”

  • “Modulation of wound microenvironment after acute trauma”

  • “Topical application of growth factors in burn wounds”

  • “Strategies for improving graft integration in skin reconstruction”

  • “The role of inflammation in chronic wound healing”

  • “Clinical outcomes of face transplantation procedures”

  • “Advancements in vascularized composite allotransplantation”

  • “Application of tissue-engineered scaffolds in wound care”

  • “NIH-funded translational research in acute wound management”

  • “Gene expression profiling of wound healing phases”

  • “Controlled delivery systems for wound therapeutics”

  • “Collagen remodeling and scar minimization techniques”

  • “Defense-sponsored innovations in trauma wound therapy”

  • “Multidisciplinary approaches to facial reconstruction”

  • “Clinical trials in bioengineered skin substitutes”

Shuang Guo | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Published on by Citation Awards

Shuang Guo | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Dr Shuang Guo, Tsinghua University Affiliated Beijing Tsinghua Changgung Hospital: Beijing Tsinghua Changgung Hospital, China

Dr. Shuang Guo is a dedicated postdoctoral researcher at Beijing Tsinghua Changgung Hospital, affiliated with the School of Clinical Medicine at Tsinghua University. With a Ph.D. in Clinical Medicine from the prestigious Huazhong University of Science and Technology, Dr. Guo has contributed significantly to the field of cardiovascular and genetic diseases. Her multidisciplinary research approach bridges clinical practice with cutting-edge molecular science, emphasizing hereditary arrhythmias, hypertension, and vascular disorders. Dr. Guo has published influential articles in international journals and is actively involved in innovation, holding several patents related to vascular health and gastrointestinal treatments. As a passionate investigator and co-developer of novel diagnostic and therapeutic strategies, she consistently pushes the boundaries of translational medicine. Dr. Guo’s dedication to scientific excellence and patient-centered research continues to enhance understanding and treatment of complex hereditary and vascular diseases in China and beyond.

Publication Profile

orcid

Education 

Dr. Shuang Guo earned her Ph.D. in Clinical Medicine from the Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, one of China’s top institutions in medical education and biomedical research. During her doctoral training, she cultivated a solid foundation in cardiovascular pathology, molecular diagnostics, and translational medicine. Her academic journey was marked by hands-on clinical exposure combined with deep exploration of hereditary diseases, enabling her to integrate lab-based discoveries with bedside care. The program offered her robust mentorship and multidisciplinary collaboration opportunities that enhanced her clinical insight and research acumen. This rigorous educational experience provided the basis for her continued research excellence and led directly to her postdoctoral appointment at Tsinghua University. Her academic background also includes comprehensive training in medical genetics, vascular physiology, and clinical trial design, which continues to inform her postdoctoral investigations into novel treatments and personalized care for cardiovascular and hereditary disorders.

Experience

Currently serving as a postdoctoral researcher at Beijing Tsinghua Changgung Hospital, affiliated with the School of Clinical Medicine, Tsinghua University, Dr. Shuang Guo focuses on vascular biology, hereditary cardiovascular diseases, and precision medicine. Her postdoctoral work includes conducting high-impact research, co-authoring clinical trials, and filing patents on molecular therapies for gastrointestinal and vascular diseases. She collaborates with a multidisciplinary team of clinicians, biologists, and bioengineers to translate laboratory findings into therapeutic solutions. Before her postdoc, she gained extensive research experience at Huazhong University of Science and Technology, where she contributed to translational cardiovascular studies and clinical case analyses at Union Hospital. Dr. Guo is also actively engaged in manuscript writing, grant applications, and patent development, underscoring her commitment to innovation and collaboration. Her professional journey demonstrates a strong intersection of research excellence and clinical relevance, with a focus on improving diagnostic and therapeutic outcomes in genetically mediated and vascular-related conditions.

Awards and Honors

While specific named awards are not listed, Dr. Shuang Guo’s contributions to the medical and scientific community are demonstrated through her leadership as first author in multiple peer-reviewed journals, co-first authorship in a major JACC publication, and her involvement in five innovative patents related to gastrointestinal and vascular health. Her research has garnered recognition in respected publications such as Genes, Journal of Vascular Surgery, and JACC: Basic to Translational Science, reflecting high scholarly merit. These achievements speak to her excellence in both foundational research and applied clinical studies. Dr. Guo’s role in inventing novel uses of inulin, identifying mutation genes associated with hypercholesterolemia, and contributing to the development of therapeutic applications for short-chain fatty acids highlights her contribution to innovation. Her growing reputation in cardiovascular and hereditary disease research underscores her role as a rising scientific leader. Future recognition is likely as her contributions continue to impact global healthcare.

Research Focus

Dr. Shuang Guo’s research is rooted in clinical and molecular investigation of hereditary cardiovascular and gastrointestinal diseases. Her primary focus areas include genetic arrhythmias, monogenic hypertension, vascular inflammation, and abdominal aortic aneurysms. She is particularly interested in translational research—bridging the gap between genetic findings and clinical applications. Her work explores the therapeutic potential of dietary fibers like inulin and microbiota-derived short-chain fatty acids in modulating immune responses and vascular health. Dr. Guo’s ongoing studies involve identifying novel genetic mutations linked to hypercholesterolemia and other inherited conditions. She applies molecular biology, clinical diagnostics, and bioinformatics to uncover mechanisms underlying disease progression. Her research also emphasizes the role of immune modulation in disease treatment, especially via regulatory T-cell activity in vascular disorders. Through multidisciplinary collaboration, she aims to develop minimally invasive strategies and precision-based therapies to improve patient care, focusing on personalized medicine in complex, genetically-influenced disease models.

Publication Top Notes

  • 📘 Pathogenesis and Clinical Characteristics of Hereditary Arrhythmia Diseases – Genes, 2024.

  • 📗 Selective Minimally Invasive Strategy for Acute Superior Mesenteric Artery Obstruction – Journal of Vascular Surgery, 2025.

  • 📙 Propionate Alleviates Abdominal Aortic Aneurysm by Modulating Colonic Regulatory T-Cell Expansion and Recirculation – JACC: Basic to Translational Science, 2022.

  • 📕 Research Advances in Monogenic Inherited Hypertension – 中国医学前沿杂志(电子版), 2024

Anna Lankoff | Genetics and Molecular Biology | Best Researcher Award

Published on by Citation Awards

Anna Lankoff | Genetics and Molecular Biology | Best Researcher Award

Prof Anna Lankoff, Institute of Nuclear Chemistry and Technology, Centre for Radiobiology and Biological Dosimetry, Poland

Prof. Anna Lankoff is a distinguished scientist and educator renowned for her contributions to genotoxicology, nanotoxicology, and radiobiology. 👩‍🔬🧪 With over three decades of experience, she has made groundbreaking advancements in the study of ionizing radiation-induced DNA damage, nanoparticle-based radioconjugates for cancer therapy, and cellular responses to nanomaterials. 🌐🔬 Currently, she holds full professorships at both the Institute of Nuclear Chemistry and Technology in Warsaw and Jan Kochanowski University in Kielce, where she leads the Cytogenetics and Genotoxicology Laboratories. 💡📘 Her collaborative work spans across institutions in Germany, Finland, Belgium, and the USA. She is a respected academic leader, actively participating in global expert committees including WHO-IARC and the European Radiation Research Council. 🌍📚 With 85 peer-reviewed papers, 3797 citations, and an h-index of 30, Prof. Lankoff exemplifies excellence in research and education, making her an ideal candidate for the Best Researcher Award. 🏆🔝

Publication Profile

Orcid

Education 

Prof. Anna Lankoff began her academic journey with an MSc in Biology (1986–1991) from Jan Kochanowski University, Kielce, Poland. 🎓🔬 She earned her PhD in Toxicology in 1999 from Maria Sklodowska-Curie University in Lublin, Poland. 💊📘 Her research prowess led her to complete a prestigious postdoctoral fellowship in 2003 at Wright State University in Dayton, Ohio, USA, in the Department of Biological Sciences. 🌍🧬 In 2007, she achieved her DSc (habilitation) in Biological Sciences from the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences. 🧫📖 By 2014, she was awarded the title of Full Professor in Biological Sciences, marking a significant milestone in her academic career. 🌟 Her extensive academic preparation laid the foundation for a prolific scientific and educational path in radiobiology, cytogenetics, and nanotoxicology. 🧠💼

Experience 

Prof. Lankoff has an extensive academic and research career. Since 2014, she has been a Full Professor at both the Institute of Nuclear Chemistry and Technology, Warsaw, and Jan Kochanowski University, Kielce. 🧪🇵🇱 She leads laboratories in cytogenetics and genotoxicology. From 2009–2014, she served as Associate Professor at these institutions, and previously, as a lecturer and assistant since 1991. 📘👩‍🏫 Her international experience includes research stints at University of Duisburg-Essen (Germany), Wright State University (USA), VITO (Belgium), and Åbo Akademi University (Finland). 🌐🔍 She has mentored numerous students and professionals in molecular biology, immunology, and nanotoxicology. Her professional journey reflects dedication to excellence in both teaching and cutting-edge scientific research. 💡🧬

Awards and Honors 

Prof. Anna Lankoff’s contributions have been recognized internationally. 🌟 She was a working group member for the WHO-IARC (2006) and an expert for the EU’s “Epigenetic effects” radiation protection group (2017). 🌍🔬 She represented Poland on the ISO Radiology Standards Committee (2010–2015) and serves on the Scientific Council of the Institute of Nuclear Chemistry and Technology and the Polish Society for Radiation Research. 🇵🇱📘 She is also a member of the European Radiation Research Council since 2022. 🧪💡 Her work has earned her recognition for developing standards in biological dosimetry and contributions to nanotoxicology and radiation biology. 📜🔝 With a prolific academic record of 85 JCR-listed publications and over 3,700 citations, she holds an h-index of 30. 📚 Her impactful global collaborations, editorial work, and advisory roles highlight her as a true leader in radiobiological research and innovation. 🧬🏆

Research Focus 

Prof. Lankoff’s research integrates nanotechnology, radiobiology, and molecular biology. 🧬 Her focus areas include the genotoxicity and cytotoxicity of nanomaterials, development of nanoparticle-based radioconjugates for targeted cancer diagnosis and therapy, and the mechanisms of DNA damage and repair induced by ionizing radiation. 💥🧪 She investigates cellular responses such as cell cycle arrest, apoptosis, and pyroptosis in reaction to nanomaterial exposure and radiation treatment. 🧫 Her recent work explores nanotheranostics, blackcurrant-derived antioxidants, and radiosensitization strategies using natural compounds. 🌿💉 She also delves into biodistribution, pharmacokinetics of engineered nanostructures, and radiobiological safety, bridging basic science with translational medicine. 🌐🧠 Prof. Lankoff’s innovative research contributes to the development of safer nanomaterials and more effective cancer therapies, reinforcing her status as a pioneering researcher in modern molecular and radiation biology. 🧪🔬📈

Publication Top Notes

  1. 📘 Advances in Nanotheranostic Systems for Concurrent Cancer Imaging and Therapy: An Overview of the Last 5 Years (2024)

  2. 🧪 Nanoparticle-Based Radioconjugates for Targeted Imaging and Therapy of Prostate Cancer (2023)

  3. ☢️ Hypothermia Modulates NBS1, γH2AX and 53BP1 Foci in U2OS Cells Post Gamma Radiation (2022)

  4. 🍇 Blackcurrant Pomace Protects Rats from Testicular Oxidative Stress from Biodiesel Exhaust (2022)

  5. 🔬 Surface Modification of Gold Nanoparticles Triggers Pyroptosis-Inducing Cytokine Release (2022)

  6. 💉 Targeted NaA Nanozeolites for Prostate Cancer Therapy: Toxicity and Pharmacokinetics (2021)

  7. 🧬 Cisplatin Lowers Radiotherapy-Induced Micronuclei in Lymphocytes of Gynaecological Cancer Patients (2021)

  8. 📈 Coralyne Radiosensitizes A549 Cells by CDKN1A Upregulation Affecting G2/M Cell Cycle Arrest (2021)

 

Abimbola Arise | Biochemistry, Genetics and Molecular Biology | Best Research Article Award

Published on by Citation Awards

Abimbola Arise | Biochemistry, Genetics and Molecular Biology | Best Research Article Award

Dr. Abimbola Arise, University of Ilorin, Kwara State, Nigeria

Dr. Abimbola Kemisola Arise (née Jayeoba) is an esteemed researcher and academic in Food Science and Technology. Born on July 5, 1977, she currently serves in the Department of Home Economics and Food Science. She began her academic career as an Assistant Lecturer in 2011 and has since contributed significantly to food research, focusing on food safety, protein characterization, and product development. A dedicated scholar, she has published extensively in international journals and authored book chapters on sensory evaluation and functional food properties. Dr. Arise is a passionate mentor and an active member of multiple professional societies, including the Nigerian Institute of Food Science and Technology (NIFST) and the South African Association for Food Science and Technology. She has also received awards for her outstanding research contributions. Her expertise in food biochemistry and technology continues to impact both academia and industry.

Publication Profile

google scholar

Education 🎓

Dr. Abimbola Kemisola Arise (née Jayeoba) is an esteemed researcher and academic in Food Science and Technology. Born on July 5, 1977, she currently serves in the Department of Home Economics and Food Science. She began her academic career as an Assistant Lecturer in 2011 and has since contributed significantly to food research, with a focus on food safety, protein characterization, and product development. A dedicated scholar, she has published extensively in international journals and authored book chapters on sensory evaluation and functional food properties. Dr. Arise is a passionate mentor and an active member of multiple professional societies, including the Nigerian Institute of Food Science and Technology (NIFST) and the South African Association for Food Science and Technology. She has also received awards for her outstanding research contributions. Her expertise in food biochemistry and technology continues to impact both academia and industry, fostering advancements in nutritional science, product innovation, and food safety standards.

Experience

Dr. Arise has over a decade of experience in academia and food research. She joined the University of Ilorin as an Assistant Lecturer in 2011 and has progressed through the ranks due to her research excellence. Her career has been dedicated to teaching and mentoring students in Food Science and Technology, with a strong emphasis on applied research and industry collaboration.She has led multiple research projects focusing on food safety, functional food development, and protein characterization. Dr. Arise also participates in peer review activities, contributing as a reviewer for reputable scientific journals. Beyond academia, she engages with professional organizations and has presented her findings at international and national conferences.Her experience extends to supervising undergraduate and postgraduate students, developing innovative food products, and collaborating with industry professionals to advance food processing and safety standards in Nigeria and beyond.

Awards & Honors

  • 🥇 Best Poster Presenter Award – NIFST Conference, University of Ilorin (2019)

  • 🎖️ Member, Nigerian Women in Agriculture Research & Development (2019–Present)

  • 🎖️ Member, Nigerian Society of Experimental Biology (NISEB) (2013–Present)

  • 🎖️ Member, South African Association for Food Science and Technology (2014–Present)

  • 🎖️ Member, Nigerian Institute of Food Science and Technology (NIFST) (2011–Present)

Dr. Arise has been recognized for her impactful research, securing the Best Poster Award at the 2019 NIFST Conference. She is a distinguished member of several professional bodies, contributing to advancements in food science through research, mentorship, and collaborations. Her professional affiliations reflect her commitment to scientific excellence and continuous learning in the field.

Research Focus

Dr. Abimbola Kemisola Arise’s research primarily focuses on food biochemistry, functional food development, and protein extraction. She specializes in protein characterization and the functional properties of legumes, particularly exploring alternative protein sources such as Bambara groundnut 🥜. Her work in fortified and enriched food products 🌿 aims to enhance nutritional quality, while her expertise in sensory evaluation and consumer acceptability 🍪 ensures that innovative food products meet consumer preferences. She also investigates food preservation and safety techniques 🧫 to improve shelf life and reduce spoilage. Additionally, her research delves into nutritional profiling and the health benefits of indigenous foods 📉, providing insights into their potential role in public health. Dr. Arise’s studies on Moringa-enriched maize flour, Bambara groundnut proteins, and food storage techniques have contributed significantly to functional food science. She is committed to bridging the gap between scientific innovation and practical food solutions, promoting sustainable food processing technologies to minimize waste and maximize nutrient retention.

Publication Top Notes

📝 Journals

1️⃣ Effects of storage conditions and periods on glycoalkaloids content and nutritional value of Solanum tuberosum – Journal of Agricultural Research and Development (2012)
2️⃣ Acceptability and Nutritional Attributes of Moringa oleifera–enriched maize flour – Journal of Agricultural Research and Development (2012)
3️⃣ The effects of addition of moringa leaf waste fibre on proximate and sensory characteristics of cookies – Agrosearch (2013)
4️⃣ Acceptability and sensory characteristics of moringa leaf and moringa-based species in Kwara State – International Journal of Phytofuel and Allied Sciences (2014)
5️⃣ Proximate composition, functional and sensory properties of “TUWO” from maize and Bambara groundnut – Applied Tropical Agriculture (2019)
6️⃣ Comparative studies on amino acid and functional properties of black benniseed and false sesame protein concentrates – Ajayi Crowther Journal of Pure and Applied Sciences (2024)

📖 Book Chapters

7️⃣ Understanding Sensory Evaluation of Food – Food Science and Technology, Walter De Gruyter STEM (2021)
8️⃣ Bambara Groundnut Protein in Food and Potential Industrial Applications – Springer (2021)